ArticleMaterials today (Kidlington, England)2025
Aminophosphonate-Derived Lipid Nanoparticles Enable Circular RNA Delivery for Functional Recovery after Spinal Cord Injury.
Article in Materials today (Kidlington, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Spinal cord injury (SCI) is a devastating neurological disorder that results in severe disability and imposes a high social and economic burden. Effective recovery from SCI requires comprehensive neural repair strategies, including neurogenesis and neuroprotection. Inspired by the structure of phospholipids in nature, we developed a library of biomimetic ionizable lipids, containing aminophosphate, aminophosphoramidate, or aminophosphonate groups (AP lipids). Then, we formulated these AP lipids into lipid nanoparticles (LNPs) and examined their mRNA delivery efficiency in neurons and astrocytes. Among these AP LNPs, AP60 LNP showed superior delivery efficiency compared to FDA approved D-Lin-MC3-DMA (MC3) LNP. To achieve longer protein expression, the circular RNA was used in LNPs. Additionally, we developed a two-step method for circular RNA production, providing a simple yet highly efficient approach. By combining these innovations, a circular RNA loaded aminophosphonate-derived lipids nanoparticles delivery system (CROSS) was constructed. To explore a therapeutic regimen, CROSS-loaded with circular Sox2, Ascl1, and GDNF RNAs were administered locally and intravenously in SCI model, which led to the restoration of bladder function and significant motor function recovery. In summary, the CROSS platform provided a novel and effective strategy for treating SCI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.